Maastro
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment – Therapeutics
The Radiation Oncology department at Maastro leverages cutting‑edge imaging and precision radiotherapy tools to enhance treatment effectiveness for cancer patients.
- Neoadjuvant triple therapy combining chemotherapy, immunotherapy, and stereotactic ablative radiotherapy for pancreatic cancer
- Targeted radiotherapy with short‑term hormonal treatment for oligometastatic prostate disease
- Co‑analgesic methadone trial for metastatic bone pain management
By integrating innovative equipment with multidisciplinary expertise, the team aims to translate technological advances into tangible clinical benefits.
Analytical, Diagnostic, Therapeutic Techniques and Equipment – Surgical Procedures, Operative
Collaboration between surgeons and radiation oncologists at Maastro focuses on organ‑preserving strategies and optimal surgical margins for gastrointestinal tumors.
- Rectal preserving therapy after local excision versus adjuvant chemoradiotherapy
- Radical surgery compared with adjuvant treatment for early rectal cancer
- Evaluating clear resection margins in borderline resectable pancreatic cancer
The interdisciplinary approach seeks to balance curative intent with quality‑of‑life considerations for patients undergoing operative procedures.
Diseases – Digestive System Diseases
Clinical studies at Maastro target major digestive malignancies, exploring neoadjuvant regimens and targeted therapies to improve survival outcomes.
- Neoadjuvant treatment for borderline resectable pancreatic cancer
- Adding trastuzumab and pertuzumab to chemoradiation for HER2‑positive esophageal adenocarcinoma
- High‑risk locally advanced rectal cancer protocols comparing FOLFOXIRI and CAPOX/FOLFOX
These trials aim to refine therapeutic pathways and increase the proportion of patients achieving disease‑free status after treatment.
Diseases – Neoplasms
The research portfolio at Maastro encompasses a broad spectrum of solid tumors, with emphasis on molecular profiling and symptom control.
- Molecularly guided adjuvant therapy for mismatch‑repair deficient high‑risk endometrial cancer
- Pain reduction strategies for patients with bone metastasis
- Metastasis‑directed radiotherapy combined with androgen deprivation therapy for oligometastatic prostate cancer
By addressing both tumor biology and patient comfort, the program contributes to comprehensive cancer care.
Diseases – Pathological Conditions, Signs and Symptoms
Patient‑centered investigations at Maastro focus on improving symptom management and monitoring disease recurrence across cancer types.
- Evaluating methadone as an add‑on to opioids for metastatic bone pain
- Assessing three‑year recurrence‑free survival in endometrial cancer patients
- Measuring clinical complete response rates after neoadjuvant chemoradiotherapy for rectal cancer
The goal is to enhance quality of life while providing reliable metrics for long‑term treatment success.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Amsterdam UMC Stichting3active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amsterdam UMC Stichting3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Maastro
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Durvalumab as Adjuvant Therapy in Mismatch Repair-Deficient High-Risk Endometrial Cancer Post-Surgery: A Phase III Clinical Trial | Leids Universitair Medisch Centrum (LUMC) | Phase III | Recruiting | Jun 2022 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Oxaliplatin | 5 | Unknown | 2017-10-09 | 2026-03-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.